September 19, 2013
French pharmaceutical giant Sanofi-Aventis SA has agreed to pay $40 million to settle a class action brought by investors who claim the company withheld information about anti-obesity drug Zimulti's link to severe psychiatric problems, according to documents filed in New York federal court on Thursday.
March 20, 2013
A New York federal judge on Wednesday certified a class of Sanofi-Aventis SA investors who claim the French pharmaceutical giant withheld information about anti-obesity drug Zimulti's link to severe psychiatric problems, finding the lead plaintiffs' securities fraud claims were typical of the class as a whole.